- Home
- VCEL vs CCIA Comparison
VCEL vs CCIA Comparison
Compare VCEL & CCIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCEL
- CCIA
- Stock Information
- Founded
- VCEL 1989
- CCIA N/A
- Country
- VCEL United States
- CCIA
- Employees
- VCEL N/A
- CCIA N/A
- Industry
- VCEL Biotechnology: Biological Products (No Diagnostic Substances)
- CCIA
- Sector
- VCEL Health Care
- CCIA
- Exchange
- VCEL Nasdaq
- CCIA Nasdaq
- Market Cap
- VCEL 2.1B
- CCIA N/A
- IPO Year
- VCEL 1997
- CCIA 2023
- Fundamental
- Price
- VCEL $41.46
- CCIA $25.70
- Analyst Decision
- VCEL Strong Buy
- CCIA
- Analyst Count
- VCEL 8
- CCIA 0
- Target Price
- VCEL $62.00
- CCIA N/A
- AVG Volume (30 Days)
- VCEL 450.2K
- CCIA N/A
- Earning Date
- VCEL 07-31-2025
- CCIA N/A
- Dividend Yield
- VCEL N/A
- CCIA N/A
- EPS Growth
- VCEL 521.85
- CCIA N/A
- EPS
- VCEL 0.05
- CCIA N/A
- Revenue
- VCEL $238,541,000.00
- CCIA N/A
- Revenue This Year
- VCEL $23.03
- CCIA N/A
- Revenue Next Year
- VCEL $24.52
- CCIA N/A
- P/E Ratio
- VCEL $702.91
- CCIA N/A
- Revenue Growth
- VCEL 14.80
- CCIA N/A
- 52 Week Low
- VCEL $37.39
- CCIA N/A
- 52 Week High
- VCEL $63.00
- CCIA N/A
- Technical
- Relative Strength Index (RSI)
- VCEL 46.36
- CCIA 57.49
- Support Level
- VCEL $40.53
- CCIA $25.55
- Resistance Level
- VCEL $43.57
- CCIA $25.64
- Average True Range (ATR)
- VCEL 1.70
- CCIA 0.12
- MACD
- VCEL -0.12
- CCIA 0.01
- Stochastic Oscillator
- VCEL 34.04
- CCIA 100.00
About VCEL Vericel Corporation
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
About CCIA Carlyle Credit Income Fund 8.75% Series A Preferred Shares due 2028
Carlyle Credit Income Fund is a non-diversified, closed-end management investment company. The Fund's primary investment objective is to generate current income, with a secondary objective to generate capital appreciation. The Fund seeks to achieve its investment objective by investing predominantly in equity and junior debt tranches of collateralized loan obligations, that are collateralized by a portfolio consisting mainly of below-investment-grade U.S. senior secured loans with a large number of distinct underlying borrowers across various industry sectors.